$0.70
+0.00 (+0.07%)
Open$0.70
Previous Close$0.70
Day High$0.72
Day Low$0.69
52W High$4.31
52W Low$0.56
Volume—
Avg Volume32.6K
Market Cap20.26M
P/E Ratio—
EPS$-3.59
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,685.0% upside
Current
$0.70
$0.70
Target
$12.42
$12.42
$7.12
$12.42 avg
$14.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 30.20M | 26.52M | 10.25M |
| Net Income | -104,336,504 | -82,457,721 | 2.27M |
| Profit Margin | -345.5% | -328.2% | 22.1% |
| EBITDA | -81,220,504 | -67,755,074 | 3.06M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | +13.9% | +13.9% | +24.9% |
| Debt/Equity | 4.75 | 4.75 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |